





# ONCOBIOLOGICS PIPELINE

Biosimilar Candidate	Brand Equivalent	2014 WW Sales (\$bn)	Commercial Rights	Product Characterization	Clone Selection	Lab Scale Similarity	Phase I	Phase III	Upcoming Milestones
ONS-3010 (Adalimumab)	HUMIRA®	\$14.1	Worldwide (ex-China, India and Mexico)						Phase 3 Trial 2018
ONS-1045 (Bevacizumab)	AVASTIN®	6.9	Worldwide (ex-China, India and Mexico)						Phase 3 Trial 2018
ONS-1050 (Trastuzumab)	HERCEPTIN®	6.8	Worldwide						Phase 1 Trial 2018
ONS-4010 (Denosumab)	PROLIA®/ XGEVA®	2.7	Worldwide						Phase 1 Trial 2018